ROSHER

OFFICIAL TITLE: REAL-WORLD DATA OF CLINICOPATHOLOGICAL CHARACTERISTICS AND MANAGEMENT OF PATIENTS WITH HER2+ BREAST CANCER (ROSHER).

ROSHER SITES

home_fondo_you_barra.jpg

SPAIN

Hospital del Mar

SPAIN

Hospital de Sant Joan Despí Moisès Broggi

SPAIN

Hospital Universitario Doce de Octubre

SPAIN

Hospital Universitario Fundación Alcorcón

SPAIN

Hospital Universitari Son Espases

CLINICAL TRIAL DETAILS

THIS IS A DATA-DRIVEN, RETROSPECTIVE, LONGITUDINAL, POPULATION BASED, OBSERVATIONAL, MULTI-CENTERED STUDY USING SECONDARY DATA CAPTURED FROM CONGRUENT ELECTRONIC HEALTH RECORDS. THE TARGET POPULATION OF INTEREST IN THIS STUDY IS PATHOLOGICALLY DOCUMENTED EARLY BREAST CANCER (BC) OR LOCALLY ADVANCED BC OR DE NOVO METASTATIC BC WITH DOCUMENTED HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) AND ESTROGEN RECEPTOR (ER)/PROGESTERONE RECEPTOR (PGR) EXPRESSION STATUS AT THE TIME OF DIAGNOSIS. 

THE MAIN OBJECTIVE IS TO ASSESS THE PREVALENCE OF HER2 EXPRESSION CHANGE BETWEEN INITIAL DIAGNOSIS BETWEEN INITIAL DIAGNOSIS VERSUS ANY OF SUBSEQUENT BREAST CANCER RELAPSES.


 

TUMOR TYPE

PHASE

BREAST

N/A

2000 (N1)

30000 (N2)

10

Spain

N

SITES

COUNTRY

STATUS

Recruiting